0001140361-14-039584.txt : 20141030
0001140361-14-039584.hdr.sgml : 20141030
20141030192730
ACCESSION NUMBER: 0001140361-14-039584
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141028
FILED AS OF DATE: 20141030
DATE AS OF CHANGE: 20141030
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HASTINGS PAUL J
CENTRAL INDEX KEY: 0001309702
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 141184512
MAIL ADDRESS:
STREET 1: 61 HARTFORD STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94114
4
1
doc1.xml
FORM 4
X0306
4
2014-10-28
0
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001309702
HASTINGS PAUL J
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
1
1
0
0
Chairman & CEO
Common Stock
2014-10-28
4
M
0
8384
1.43
A
31615
D
Common Stock
2014-10-28
4
S
0
8384
22.0806
D
23231
D
Common Stock
2014-10-29
4
M
0
8385
1.43
A
31616
D
Common Stock
2014-10-29
4
S
0
8385
21.8984
D
23231
D
Common Stock
324840
I
See Footnote
Stock Option (Right to Buy)
1.43
2014-10-28
4
M
0
8384
0.00
D
2017-01-11
Common Stock
8384
51123
D
Stock Option (RIght to Buy)
1.43
2014-10-29
4
M
0
8385
0.00
D
2017-01-11
Common Stock
8385
42738
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 22, 2014.
Includes 22,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
Includes 731 shares acquired under the Issuer's Employee Stock Purchase Plan on August 29, 2014
This transaction was executed in multiple trades in prices ranging from $21.79 to $22.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $21.31 to $22.15, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012.
The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.
/s/ Alicia J. Hager, Attorney-in-Fact for Paul J. Hastings
2014-10-30